Cigna Files 8-K on Feb 7 for Feb 5 Event; Details Pending

TL;DR

**Cigna filed an 8-K, signaling an upcoming disclosure; stay tuned for details.**

AI Summary

The Cigna Group filed an 8-K on February 7, 2024, reporting an event that occurred on February 5, 2024. This filing is categorized under "Other Events" and "Financial Statements and Exhibits." While the specific details of the event are not provided in this summary, the filing indicates that Cigna, a major health services company, is updating its public record. This matters to investors because 8-K filings often precede significant announcements, and shareholders should monitor for further details that could impact the company's financial health or strategic direction.

Why It Matters

This 8-K signals that Cigna has an important event to disclose, and investors should watch for subsequent filings or announcements to understand the full implications for the company's stock.

Risk Assessment

Risk Level: medium — The risk is medium because an 8-K for 'Other Events' without immediate detail creates uncertainty, which could be positive or negative for the stock.

Analyst Insight

A smart investor would add Cigna to their watchlist and set up alerts for any subsequent filings or press releases that provide details on the 'Other Event' mentioned in this 8-K, as this could significantly impact the stock price.

Key Numbers

• 001-38769 — Commission File Number (identifies Cigna's filings with the SEC)
• 82-4991898 — IRS Employer Identification No. (Cigna's tax identification number)
• 2024-02-05 — Date of earliest event reported (the date the event being reported in the 8-K occurred)
• 2024-02-07 — Date of Report (the date the 8-K was filed with the SEC)

Key Players & Entities

• The Cigna Group (company) — registrant filing the 8-K
• Delaware (company) — state of incorporation for The Cigna Group
• New York Stock Exchange, Inc. (company) — exchange where Cigna's Common Stock is registered
• $0.01 (dollar_amount) — par value of Cigna's Common Stock

Forward-Looking Statements

• Cigna will release further details about the 'Other Event' reported in this 8-K. (The Cigna Group) — high confidence, target: 2024-02-14

FAQ

From the Filing

0001140361-24-005982.txt : 20240207 0001140361-24-005982.hdr.sgml : 20240207 20240207082739 ACCESSION NUMBER: 0001140361-24-005982 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240205 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240207 DATE AS OF CHANGE: 20240207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Group CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 24602293 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Cigna Corp DATE OF NAME CHANGE: 20181221 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 ny20020170x2_8k.htm FORM 8-K false 0001739940 NYSE 0001739940 2024-02-05 2024-02-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2024 The Cigna Group (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS Employer Identification No.) 900 Cottage Grove Road Bloomfield , Connecticut 06002 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: ( 860 ) 226-6000 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01 Other Events. On February 5, 2024, The Cigna Group (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Wells Fargo Securities, LLC, as representatives of the underwriters named in Schedule I thereto, with respect to the issuance and sale by the Company of $1 billion in aggregate principal amount of its 5.000% Senior Notes due 2029 (the “2029 Notes”), $750 million in aggregate principal amount of its 5.125% Senior Notes due 2031 (the “2031 Notes”), $1.25 billion in aggregate principal amount of its 5.250% Senior Notes due 2034 (the “2034 Notes”) and $1.5 billion in aggregate principal amount of its 5.600%